Navigation Links
Optimizing cell therapy against tumors is a balancing ACT

Adoptive cell transfer (ACT) therapy is used to treat patients with metastatic solid tumors. ACT involves the removal of some of the patient's cancer cells, and some of their immune T cells. When the cells are mixed together, specific parts of the cancer cells that stimulate the T cells to cause an immune attack can be identified. The T cells get expanded and re-infused into the patient to mount an immunological, anti-cancer response against the tumors. One of the challenges faced is selecting the appropriate T cells with proper antigen specificity.

In a new study appearing in the June 1 print issue of The Journal of Clinical Investigation, Nicholas Restifo and colleagues identified which cells are optimal for treating large, vascularized, established tumors. The authors use a mouse model that mimics the human clinical situation. They find that phenotypic and functional qualities of T cells are associated with the ability of ACT to cause regression of large, established melanomas. Seemingly paradoxical, naïve and early effector T cells are more effective for tumor treatment than more differentiated T cells.

In an accompanying commentary, Daniel Speiser and Pedro Romero write, "optimal therapeutic efficacy may depend on different T cell selection and preparation strategies" and these findings indicate that a pragmatic strategy for ACT is to keep the in vitro T cell expansion phase as short as possible to keep them naïve. These findings are important for development of improved adoptive immunotherapy approaches for treating tumors and established infectious diseases.

TITLE: Acquisition of full effector function in vitro paradoxically impairs the in vivo anti-tumor efficacy of adoptively transferred CD8+ T cells

TITLE: Towards improved immunocompetence of adoptively transferred CD8+ T cells


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Optimizing cell therapy against tumors balancing ACT

(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market announces that its Wocket® smart wallet will ... the Mark", scheduled to air on WABC Radio (am770) in ... . The broadcast air- time for the ... EST. NXT-ID, Inc.,s CEO Gino Pereira will be ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... female hormone estrogen is known to offer protection for the heart, ... New research from the University of California at Merced finds that ... a greater impact on girls, blood pressure than it does on ... between 13 and 17 years old, obese boys were 3.5 times ...
... reached epidemic levels, and pediatricians are on the front ... pre-conference session at 11:30 a.m. Friday, Oct. 14, before ... Exhibition in Boston. The Pediatrics for the ... Innovations in Practice," challenges pediatricians to "step it up ...
... Oct. 11, 2011 Based on its recent analysis ... with the 2011 North American Frost & Sullivan Award ... Biometric Platform™ , - the first scalable, multi-modal biometrics ... iris recognition from a single server. To ...
Cached Biology News:Gender differences in blood pressure appears as early as adolescence 2Pediatricians aim to end childhood obesity within a generation 2Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 2Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 3Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 4
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... The ... 7.76% of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On ... offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... Need a new look on life? Ingineos new ... Centras are multimedia sunglasses with a built-in 16-bit color LCD ... the lawn or riding the subway reality. , ,The glasses ... lens which allows users to watch video content while staying ...
... Wis. Rayovac Corp. , a force in the ... to an Atlanta, Ga. suburb in May. , ,According ... will move south. The announcement came as a surprise to ... the chance to try to work with [Rayovac], said Melanie ...
... Energy Efficiency , ,With deregulation of the retail ... two, it appears to be a time to return to ... should revisit the original text for the regulation of public ... Wisconsins position on energy policy states in WI State Statute ...
Cached Biology Technology:Rayovac to Relocate Headquarters 2Wisconsin Should Create, like Renewables, an Energy Efficient Portfolio 2Wisconsin Should Create, like Renewables, an Energy Efficient Portfolio 3Wisconsin Should Create, like Renewables, an Energy Efficient Portfolio 4
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Biology Products: